Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Salmeterol Effect on Exercise Performance

NCT06655012 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2024-10-31
Last updated
2025-04-09

Condition(s) studied

Healthy

Investigational drug(s) / intervention(s)

Salmeterol →Placebo

Salmeterol: Participants are administered 200 µg salmeterol (8 puffs) from a MDI device

Placebo: Participants are administered placebo (8 puffs) from a MDI device

Study summary

The purpose of the project is to investigate the muscle anabolic response to acute beta2-adrenergic stimulation in young healthy men and women.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Inclusion Criteria: * Age 18-40 * Physically active \>5 hours a week * Maximum oxygen uptake classified as high or very high Exclusion Criteria: * Active smoker currently or within the past 5 years * Regular intake of medication deemed by the responsible study physician to affect the test parameters (hormonal contraception is accepted for women) * Chronic or acute illness deemed by the responsible study physician to affect the test parameters * Deviation from the study protocol * Lean mass index \>21 kg/m² * Pregnancy * Smoker * Blood donation during the past 3 months

Primary outcome measure(s)

  • Power output during sprint testing — Through study completion, an average on 2 weeks
    Power output measured in Watts during a sprint on a bike ergometer

Trial sites (1)

FacilityCityRegionStatus
August Krogh Building Copenhagen Denmark Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06655012 on ClinicalTrials.gov ↗ ← All trials in Denmark